We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018.
- Authors
Nakayama, Izuma; Takahari, Daisuke; Shimozaki, Keitaro; Chin, Keisho; Wakatsuki, Takeru; Ogura, Mariko; Ooki, Akira; Kamiimabeppu, Daisaku; Osumi, Hiroki; Shinozaki, Eiji; Yamaguchi, Kensei
- Abstract
Background In the past decade, several successful clinical trials provided new therapeutic agents approved for advanced gastric cancer (AGC). This study evaluated whether these practice-changing results actually altered the clinical practice. Patients and Methods We retrospectively reviewed medical records of treatment-naive AGC patients who received combination chemotherapy of fluoropyrimidine and platinum between 2007 and 2018 and divided them into three groups: Groups A (2007-10), B (2011-14), and C (2015-2018), respectively. We compared the clinicopathological features, treatment details, and clinical outcomes among the three groups. Results In total, 1004 consecutive patients were enrolled (A; n = 254, B; n = 300, and C; n = 450). The number of patients with poor performance status, older age, esophagogastric junction adenocarcinoma, and primary tumor increased during the study period. All groups had similar median overall survival (OS); ~16 months) without any statistical difference but steady prolongation of survival was observed in the adjusted with imbalance prognostic factors among groups (B/A; hazard ratio, HR 0.82, 95% C.I 0.68-0.98, C/A; HR 0.72, 95% CI 0.60-0.86); OS of HER2-positive AGC patients was clearly improved (HER2-positive vs HER2-negative in Group B, HR 0.80, 95% CI 0.60-1.06; Group C, HR 0.68, 95% CI 0.51-0.90) but that of diffuse-type AGC patients remained dismal. Conclusions The increasing availability of chemotherapy options potentially contributed to improved survival of AGC patients, but expanded chemotherapeutic indications made the survival benefit inconspicuous in the whole population. Future therapeutic development for the AGC subset not adequately receiving benefit from previous clinical trials is warranted.
- Subjects
JAPAN; STOMACH tumors; EVALUATION of medical care; SPECIALTY hospitals; CANCER relapse; ACQUISITION of data; RETROSPECTIVE studies; CANCER patients; CANCER treatment; CLINICAL medicine; MEDICAL records; PHYSICIAN practice patterns
- Publication
Oncologist, 2022, Vol 27, Issue 6, pe506
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1093/oncolo/oyab069